PA-50/PA-41 antitoxin antibody therapy for C. difficile infection

描述(申请人提供)：艰难梭菌感染(CDI)是美国医院获得性腹泻和肠道感染死亡的主要原因。CDI的发病率和严重性在过去十年中急剧增加，部分原因是异常毒力和致命菌株的出现和全球传播，这些菌株过度表达A和B两种毒素。这些强大的细胞毒素代表艰难梭菌的主要毒力因子，可以破坏结肠内的细胞，导致液体分泌和炎症。CDI通常是由抗生素的使用引起的，抗生素扰乱了保护性的结肠菌群，为艰难梭菌的繁衍提供了机会。口服万古霉素或甲硝唑可缓解许多患者的症状，但复发频繁。对于多次复发的CDI或严重的危及生命的疾病，目前还没有标准的治疗方法。开发新的治疗策略是全球卫生领域的当务之急。一种实验性的治疗策略是用单抗(MAbb)中和毒素。抗毒素单抗是一种非抗生素疗法，旨在阻止毒素的有害影响，同时允许正常的结肠菌群反弹和结肠自然愈合。第一代抗毒素单抗在预防CDI复发方面显示出临床活性，但在治疗活动期疾病方面尚不具有临床活性。我们已经产生了高度有效的人源化单抗，命名为PA-50和PA-41，分别针对毒素A和B的新的中和表位。与第一代单抗相比，PA-50和PA-41在体外中和BI/NAP1/027强毒株毒素的能力是第一代单抗的1000倍。在一个公认的CDI仓鼠模型中，PA-50/PA-41治疗提供了长期保护(95%的存活率)，而第一代单抗延迟但不能防止死亡(0%存活率)。像PA-50和PA-41这样的高效单抗既有可能打破多次复发CDI患者的感染循环，也有可能治疗危及生命和具有挑战性的CDI病例。该项目的总体目标是完成我们的主要单抗的临床前研究，并获得FDA的同意，启动人体试验。初步的临床前研究将描绘PA-50和PA-41强大的毒素中和活性的分子和机制基础；这些研究也将为艰难梭菌中毒的生物学提供新的见解。我们还将在新建立的CDI仔猪模型中检验mAbs对BI/NAP1/027菌株引起的活动性疾病的治疗效果。额外的翻译活动旨在完成为PA-50和PA-41准备和提交研究性新药申请所需的基本制造、毒理学和其他开发活动。如果成功，将为PA-50和PA-41的人体临床试验做好准备，并将成为可能应对艰难梭菌疫情的关键挑战的创新新制剂开发的一个关键里程碑。 与公共卫生相关：艰难梭菌是一种芽胞形成细菌，是医院获得性腹泻的主要原因，在美国每年影响约50万人。近年来出现了异常致命的菌株，迫切需要新的治疗方法。艰难梭菌感染(CDI)通常会袭击服用抗生素的人，这会破坏具有保护作用的肠道微生物，并为艰难梭菌提供蓬勃发展的机会。艰难梭菌产生的毒素可以破坏大肠内的细胞。一种实验性的治疗策略是用单抗阻断毒素的有害影响。我们已经开发出新的抗体，可以在CDI的临床前模型中有效地中和艰难梭菌毒素。在这个项目中，我们寻求完成的研究将使我们的抗毒素抗体作为CDI的非抗生素疗法进行临床测试。

DESCRIPTION (provided by applicant): Clostridium difficile infection (CDI) is the leading cause both of hospital-acquired diarrhea and of death due to intestinal infections in the US. The incidence and severity of CDI have increased sharply over the past decade due in part to the emergence and worldwide spread of unusually virulent and deadly strains that overexpress two toxins, A and B. These potent cytotoxins represent the main virulence factors of C. difficile and can damage cells that line the colon, resulting in fluid secretion and inflammation. CDI typically is precipitated by the use of antibiotics, which disrupt the protective colonic flora and provide an opportunity for C. difficile to flourish. Treatment with oral vancomycin or metronidazole leads to symptom resolution in many patients; however, relapse occurs frequently. There is no standard therapy for multiply recurrent CDI or severe, life-threatening disease. Development of new treatment strategies is a global health imperative. One experimental treatment strategy is to neutralize the toxins with monoclonal antibodies (mAbs). Antitoxin mAbs represent a non-antibiotic therapy that is designed to block the harmful effects of the toxins while allowing the normal colonic flora to rebound and the colon to heal naturally. First-generation antitoxin mAbs have shown clinical activity in preventing recurrence of CDI but not in treating active disease. We have generated highly potent humanized mAbs, designated PA-50 and PA-41 that are directed to novel neutralization epitopes on toxins A and B, respectively. Compared with first-generation mAbs, PA-50 and PA-41 are 1,000-fold more potent in neutralizing toxins from virulent BI/NAP1/027 strains in vitro. In a well-established hamster model of CDI, treatment with PA-50/PA-41 provided long-term protection (95% survival) from a lethal challenge, whereas first-generation mAbs delayed but did not prevent death (0% survival). Highly potent mAbs like PA-50 and PA-41 have the potential both to break the cycle of infection in patients with multiply recurrent CDI and to treat life-threatening and otherwise challenging cases of CDI. The overall goal of this project is to complete preclinical studies of our lead mAbs and obtain agreement from FDA to initiate human testing. Initial preclinical studies will delineate the molecular and mechanistic underpinnings of the potent toxin-neutralizing activities of PA-50 and PA-41; these studies will also provide new insights into the biology of C. difficile intoxication. We also will examine the efficacy of the mAbs in treating active disease caused by BI/NAP1/027 strains in a newly established piglet model of CDI. Additional translational activities are designed to complete essential manufacturing, toxicology and other development activities required to prepare and submit Investigational New Drug applications (INDs) for PA-50 and PA-41. Success would ready PA-50 and PA-41 for human clinical testing and would constitute a key milestone in the development of innovative new agents that may address key challenges of the C. difficile epidemic. PUBLIC HEALTH RELEVANCE: Clostridium difficile is a spore-forming bacterium that represents the leading cause of hospital-acquired diarrhea and affects approximately 500,000 individuals annually in the US. Unusually deadly strains have emerged in recent years, and new treatments are urgently needed. C. difficile infection (CDI) typically strikes individuals who are taking antibiotics, which can disrupt the protective gut microbes and provide an opportunity for C. difficile to flourish. C. difficile produces toxins that can damage the cells that line the large intestines. One experimental treatment strategy is to block with harmful effects of the toxins with monoclonal antibodies. We have developed novel antibodies that potently neutralize C. difficile toxins in preclinical models of CDI. In this project, we seek to complete studies that will ready our antitoxin antibodies for clinical testing as non- antibiotic therapies for CDI.